X4 Pharmaceuticals (XFOR) Accumulated Expenses (2017 - 2026)

X4 Pharmaceuticals (XFOR) has reported Accumulated Expenses for 10 consecutive years, with $14.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Accumulated Expenses rose 8.11% year-over-year to $14.1 million; the trailing twelve-month figure through Jun 2026 stood at $14.1 million (up 8.11% YoY), and the FY2025 full-year result was $18.6 million, down 19.13% from the prior year.
• Accumulated Expenses retreated to $14.1 million in Q2 2026 per XFOR's latest filing, from $17.1 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $23.0 million in Q4 2024 and bottomed at $6.9 million in Q1 2022.
• Historically, Accumulated Expenses has averaged $14.5 million across 5 years, with a median of $13.8 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Accumulated Expenses plunged 35.76% in 2022, then soared 79.5% in 2024.
• Over 5 years, Accumulated Expenses stood at $12.0 million in 2022, then gained by 6.5% to $12.8 million in 2023, then jumped by 79.5% to $23.0 million in 2024, then retreated by 19.13% to $18.6 million in 2025, then dropped by 24.07% to $14.1 million in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $14.1 million, $17.1 million, and $18.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.